Blood-based immune-endocrine biomarkers of treatment response in depression
- Submitting institution
-
University of Cambridge
- Unit of assessment
- 12 - Engineering
- Output identifier
- 9842
- Type
- D - Journal article
- DOI
-
10.1016/j.jpsychires.2016.08.020
- Title of journal
- Journal of Psychiatric Research
- Article number
- -
- First page
- 249
- Volume
- 83
- Issue
- -
- ISSN
- 1879-1379
- Open access status
- Not compliant
- Month of publication
- August
- Year of publication
- 2016
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
9
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- Less than half of depression patients are correctly diagnosed within primary care. The aim of our study was to develop and validate a diagnostic serum biomarker panel identified through joint effects analysis of multiplex immunoassay profiling data.We demonstrated that a blood-based biomarker-sociodemographic panel can detect depression in naturalistic healthcare settings. The findings of this study and other findings represented the basis on which a new spin-out company was formed. Psyomics received 3.8 M investments since it was founded and is now valued at ~6.5M. The University of Cambridge is a investor and share holder.
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -